Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Law Firms
Life Sciences
High-Tech
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Analyse BD's 1,267-patent innovation journey from needle safety to AI diagnostics. Three waves, key trends, and what drives BD's medtech strategy through 2026.
Article | Report Biopharma BD teams: Identify lucrative licensing opportunities using AI-powered patent analytics. Accelerate asset evaluation & diligence. Request a demo.
Article | Report Identify licensing opportunities with patent analytics. Patsnap Eureka Life Science helps BD teams find novel drug assets, assess IP, & benchmark competitors faster. Book a demo.
Article | Report Struggling to link competitor pipelines to patent families? Patsnap Eureka Life Science unifies biopharma data, extracting IP insights for CI teams. Book a demo.
Article | Report Master white space analysis in drug discovery with AI. Patsnap Eureka Life Science reveals therapeutic gaps, unmet needs, and competitive intelligence fast. Explore the platform.
Article | Report Discover top pharma patent expiration tools. Navigate regulatory exclusivity & FTO with AI-powered platforms like Patsnap Eureka Life Science. Accelerate deals—Request a demo.
Article | Report Master complex biologics FTO analysis with this expert guide. Learn essential steps and how AI-powered patent intelligence accelerates your workflow. Request a demo.
Article | Report Master patent search for chemically modified sequences like GalNAc & LNA. Discover how Patsnap Eureka Life Science's AI platform reduces FTO risk. Book a demo today.
Article | Report Monitor competitor monoclonal antibody patents with AI. Get proactive insights, extract deep data, and compare assets for strategic mAb competitive intelligence. Request a demo.
Article | Report IP professionals need biosequence search & patent legal status. Patsnap Eureka Life Science unifies both for FTO, prior art, and defensible IP opinions. Book a demo.
Article | Report How does tezepelumab's TSLP inhibition differ from IL-33 blockade (itepekimab, astegolimab) in phenotype coverage, clinical efficacy, and atopic march pipeline potential?
Article | Report APOE ε4 genotype ARIA risk multipliers and clinical decision framework for lecanemab and donanemab prescribing in Alzheimer's disease treatment.
Article | Report How do FXIa inhibitors asundexian and milvexian compare to apixaban and rivaroxaban on bleeding risk and efficacy? Patent and clinical trial evidence analysed.
Article | Report How do Tarlatamab and Elranatamab differ from gamma-delta T-cell therapies in TME penetration, cytokine release risk, and MHC-I resistance? A mechanistic analysis.
Article | Report How do patient population differences and I² heterogeneity (0%–95%) across five Lecanemab/Donanemab trials affect meta-analysis reliability and clinical applicability?